# Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules

> **NCT02193828** · PHASE2 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 76 (actual)

## Conditions studied

- Dupuytren's Disease

## Interventions

- **BIOLOGICAL:** Collagenase clostridium histolyticum
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02193828
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2017-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02193828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02193828, "Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02193828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*